Kingsview Wealth Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.22M | Sell |
24,532
-15,821
| -39% | -$1.33M | 0.03% | 536 |
|
|
2026
Q1 | $3.23M | Buy |
40,353
+149
| +0.4% | +$12.3K | 0.04% | 399 |
|
|
2025
Q4 | $3.43M | Sell |
40,204
-2,421
| -6% | -$199K | 0.05% | 361 |
|
|
2025
Q3 | $3.31M | Buy |
42,625
+17,188
| +68% | +$1.34M | 0.05% | 355 |
|
|
2025
Q2 | $1.99M | Sell |
25,437
-305
| -1% | -$22.7K | 0.03% | 438 |
|
|
2025
Q1 | $1.87M | Sell |
25,742
-55
| -0.2% | -$3.94K | 0.04% | 402 |
|
|
2024
Q4 | $1.91M | Sell |
25,797
-144
| -0.6% | -$10.1K | 0.04% | 398 |
|
|
2024
Q3 | $1.71M | Sell |
25,941
-1,183
| -4% | -$86K | 0.04% | 411 |
|
|
2024
Q2 | $2.51M | Buy |
27,124
+246
| +0.9% | +$21.8K | 0.06% | 292 |
|
|
2024
Q1 | $2.57M | Sell |
26,878
-106
| -0.4% | -$8.9K | 0.06% | 282 |
|
|
2023
Q4 | $2.06M | Buy |
26,984
+114
| +0.4% | +$7.93K | 0.06% | 272 |
|
|
2023
Q3 | $1.86M | Buy |
26,870
+524
| +2% | +$42.1K | 0.07% | 295 |
|
|
2023
Q2 | $2.49M | Hold |
26,346
| – | – | 0.1% | 212 |
|
|
2023
Q1 | $2.18M | Sell |
26,346
-543
| -2% | -$42.7K | 0.09% | 225 |
|
|
2022
Q4 | $2.01M | Sell |
26,889
-124
| -0.5% | -$9.56K | 0.09% | 236 |
|
|
2022
Q3 | $2.23M | Buy |
27,013
+29
| +0.1% | +$2.79K | 0.11% | 209 |
|
|
2022
Q2 | $2.57M | Sell |
26,984
-350
| -1% | -$36.2K | 0.12% | 185 |
|
|
2022
Q1 | $3.22M | Sell |
27,334
-325
| -1% | -$36.5K | 0.14% | 161 |
|
|
2021
Q4 | $3.58M | Buy |
27,659
+800
| +3% | +$93.3K | 0.15% | 153 |
|
|
2021
Q3 | $3.04M | Buy |
26,859
+1,185
| +5% | +$135K | 0.14% | 160 |
|
|
2021
Q2 | $2.69M | Sell |
25,674
-620
| -2% | -$58.4K | 0.13% | 171 |
|
|
2021
Q1 | $2.2M | Sell |
26,294
-124
| -0.5% | -$10.5K | 0.13% | 174 |
|
|
2020
Q4 | $2.41M | Sell |
26,418
-1,876
| -7% | -$156K | 0.17% | 134 |
|
|
2020
Q3 | $2.26M | Buy |
28,294
+730
| +3% | +$57K | 0.2% | 121 |
|
|
2020
Q2 | $1.91M | Sell |
27,564
-3,408
| -11% | -$242K | 0.19% | 133 |
|
|
2020
Q1 | $1.95M | Buy |
30,972
+14,934
| +93% | +$1.08M | 0.26% | 105 |
|
|
2019
Q4 | $1.25M | Buy |
+16,038
| New | +$1.25M | 0.16% | 170 |
|
|
2019
Q3 | – | Sell |
-8,325
| Closed | -$513K | – | 456 |
|
|
2019
Q2 | $513K | Sell |
8,325
-150
| -2% | -$9.07K | 0.09% | 242 |
|
|
2019
Q1 | $541K | Sell |
8,475
-1,950
| -19% | -$111K | 0.08% | 255 |
|
|
2018
Q4 | $532K | Sell |
10,425
-300
| -3% | -$15.2K | 0.12% | 212 |
|
|
2018
Q3 | $622K | Hold |
10,725
| – | – | 0.13% | 204 |
|
|
2018
Q2 | $520K | Hold |
10,725
| – | – | 0.12% | 190 |
|
|
2018
Q1 | $520K | Buy |
+10,725
| New | +$466K | 0.13% | 197 |
|
Other funds holding EW
Kingsview Wealth Management's EW Position: Q2 2026 in Review
Kingsview Wealth Management reduced its Edwards Lifesciences (EW) stake by 39% in Q2 2026, selling an estimated $1.33M and leaving 24,532 shares worth $2.22M. The position accounts for 0.03% of the portfolio, ranked #536.
Kingsview Wealth Management first reported a position in EW in Q1 2018 and has held it in 33 quarters since. The position peaked at $3.58M in Q4 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Kingsview Wealth Management held 24,532 shares of Edwards Lifesciences worth $2.22M as of Q2 2026.
- Kingsview Wealth Management sold 15,821 Edwards Lifesciences shares in Q2 2026, an estimated $1.33M.
- Edwards Lifesciences made up 0.03% of Kingsview Wealth Management's portfolio in Q2 2026, its #536 holding.
- Kingsview Wealth Management first reported a position in Edwards Lifesciences in Q1 2018 and has held it in 33 quarters since.
- Kingsview Wealth Management's Edwards Lifesciences position peaked at $3.58M in Q4 2021.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.